No Data
No Data
A Quick Look at Today's Ratings for Structure Therapeutics(GPCR.US), With a Forecast Between $50 to $100
Citizens Capital Markets Maintains Market Outperform on Structure Therapeutics, Lowers Price Target to $87
A Quick Look at Today's Ratings for Structure Therapeutics(GPCR.US), With a Forecast Between $80 to $93
Express News | William Blair Initiates Coverage On Structure Therapeutics With Outperform Rating
Structure Therapeutics Analyst Ratings
Promising Potential of Structure Therapeutics' Aleniglipron: A Compelling Buy Recommendation
Unlock the Full List